GET DAILY SIGNALSBridgeBio Pharma (BBIO) Posts Strong Q3 Revenue Growth on Attruby Momentum
Key Takeaways
- BridgeBio Pharma (BBIO) reported third quarter 2026 total revenue of $353.17 million, up 192.6% year over year and well above Wall Street expectations.
- Diluted earnings per share (EPS) came in at a loss of $0.42, a narrower loss than the roughly $0.56–$0.60 consensus estimate and an improvement from a loss of $0.95 a year earlier.
- U.S. net product revenue for Attruby (acoramidis), the company's treatment for ATTR-CM (transthyretin amyloid cardiomyopathy), reached $253.2 million, up about $31 million sequentially.
- License and services revenue jumped to $79.31 million, boosted by a one-time $75 million regulatory milestone, helping shrink the company's loss from operations to $11.6 million.
- Results were reported after the market close on October 29, 2026, with the stock finishing that session at $70.73.
Why These Results Matter
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, and its quarterly results now hinge on the trajectory of Attruby, its therapy for ATTR-CM, a progressive heart condition. Following a rapid launch ramp, investors are watching whether product revenue can keep compounding while the company manages spending across a pipeline poised for additional launches. The third quarter of 2026 also carried a significant milestone payment that lifted total revenue. For a company still reporting operating losses, this report offers a key read on commercial momentum, expense discipline, and the path toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
BridgeBio Pharma reported total third quarter 2026 revenue of $353.17 million, a 192.6% increase from the prior-year period and ahead of the Zacks Consensus Estimate of $296.58 million and the roughly $281.65 million consensus cited by Investing.com. Net product revenue was $253.35 million, with U.S. Attruby net product revenue of $253.2 million, up approximately $31 million sequentially and $145 million year over year. Royalty revenue was $20.51 million, while license and services revenue surged to $79.31 million, reflecting a one-time $75 million regulatory milestone.
On the bottom line, the company posted a diluted loss of $0.42 per share, an improvement from a loss of $0.95 per share a year earlier and better than consensus estimates that ranged from about $0.56 to $0.60. Loss from operations narrowed to $11.6 million, driven by higher revenue and the milestone payment.
Market Reaction and Investor Sentiment
BridgeBio Pharma shares closed at $70.73 on October 29, 2026, down a modest 0.13% on the day the results were released, suggesting investors had already priced in much of the company's commercial momentum. Sentiment heading into the print was broadly positive, supported by strong Attruby sales growth and a consensus price target above $113, with Piper Sandler recently issuing a $120 target. While the revenue and EPS beats reinforced the bull case, the muted same-day move indicates that the market's attention is increasingly turning toward forward guidance and upcoming pipeline catalysts rather than a single quarter's upside.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus first on the continued launch trajectory of Attruby and whether sequential product revenue growth can be sustained. Management has pointed to expanding sales coverage and growing first-line use, but the durability of those trends, alongside payer authorization dynamics, remains a central watch item.
A second area to monitor is spending. BridgeBio is deliberately investing in commercialization while preparing for additional launches, so the balance between revenue growth and operating expense discipline will shape how quickly losses narrow. The company has also signaled upcoming regulatory catalysts, including expected FDA reviews, which could materially influence the product pipeline and long-term revenue outlook.
Finally, the company's cash position and access to capital will be important given ongoing operating losses and a meaningful debt load. Investors will likely track gross-to-net trends for Attruby, royalty contributions from partnered products, and any new milestone or collaboration revenue, all of which affect both top-line growth and the timeline to sustained profitability.
Enhancing Analysis with AI Tools
In my own research process, I regularly rely on Tickeron’s AI Screener to quickly filter stocks by fundamentals, technical patterns, and performance metrics. It helps surface relevant ideas and compare opportunities across sectors more efficiently than manual methods, which has been useful when tracking names like BBIO alongside peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BBIO's RSI Indicator climbs out of oversold territory
The RSI Oscillator for BBIO moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 17 of the 18 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BBIO as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for BBIO just turned positive on October 01, 2026. Looking at past instances where BBIO's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.
BBIO moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 245 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for BBIO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.497) is normal, around the industry mean (3.151). P/E Ratio (-19.868) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.
Industry Biotechnology
Advertisement